Jose Manuel Otero Sells 4,666 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) COO Jose Manuel Otero sold 4,666 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $20,903.68. Following the completion of the transaction, the chief operating officer owned 137,482 shares of the company’s stock, valued at approximately $615,919.36. The trade was a 3.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jose Manuel Otero also recently made the following trade(s):

• On Monday, May 18th, Jose Manuel Otero sold 1,302 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.07, for a total value of $6,601.14.

Lexeo Therapeutics Trading Up 5.4%

Shares of NASDAQ:LXEO opened at $4.69 on Friday. Lexeo Therapeutics, Inc. has a twelve month low of $3.60 and a twelve month high of $10.99. The company has a market cap of $368.26 million, a PE ratio of -3.23 and a beta of 1.42. The company’s 50 day moving average is $5.09 and its 200 day moving average is $6.60.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Equities research analysts predict that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP boosted its holdings in Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after buying an additional 3,079 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after acquiring an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth approximately $37,000. California State Teachers Retirement System boosted its stake in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after acquiring an additional 2,148 shares during the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics during the second quarter worth approximately $50,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Chardan Capital reissued a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a report on Monday, May 11th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings cut Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.